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A B S T R A C T
This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:
Primary objective: to assess whether ACB in older adults is a prognostic factor for future cognitive decline or dementia.
Secondary objective(s): to assess whether ACB is a prognostic factor for older adults recruited in primary care, secondary care, or
community settings (with setting used as the basis for subgroup analyses); whether ACB is associated with mortality; to compare the
prognostic validity of respective ACB scales; and to examine the eFect of duration of exposure and duration of follow-up on the ACB-
dementia risk association.
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B A C K G R O U N D
Description of the condition
Cognition (or cognitive function) is the mental process of acquiring
knowledge and understanding through thought, experience, and
senses. It includes the domains of memory, language, attention,
executive functioning, and visuospatial processing. Cognitive
impairment is the disruption of functioning of any one of these
domains. Cognitive function may be assessed in detail using a
battery of neuropsychological tests covering multiple domains,
although in clinical practice, brief assessment tools such as the
Mini Mental State Examination (MMSE) or Montreal Cognitive
Assessment (MoCA) are oGen used (Folstein 1975; Nasreddine
2005).
Dementia is a syndrome of decline in cognitive function beyond
that expected from normal ageing, to an extent that interferes
with usual functioning. It may aFect memory, thinking, orientation,
comprehension, calculation, learning capacity, language, and
judgement. There are a variety of internationally accepted
diagnostic criteria for dementia, the most widely used of which
are included in the World Health Organization International
Classification of Diseases (ICD) and the American Psychiatric
Association Diagnostic and Statistical Manual of Mental Disorders
(DSM). The most recent iteration of the DSM (DSM-5) refers
to 'major neurocognitive disorder' instead of dementia. The
labels of 'dementia' or 'major neurocognitive disorder' encompass
a variety of pathologies, with specific diagnostic criteria also
available for pathologically defined dementia subtypes, such
as the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) criteria for dementia due
to Alzheimer's dementia (AD) (McKhann 1984; McKhann 2011);
McKeith criteria for Lewy body dementia (McKeith 2005); Lund
criteria for frontotemporal dementias (McKhann 2001); and the
National Institute of Neurological Disorders and Stroke and the
Association Internationale pour la Recherche et l’Enseignement
en Neurosciences (NINDS-AIREN) criteria for vascular dementia
(Román 1993).
An individual may experience a decline in cognition that is not
enough to merit a label of dementia but that is more than would be
expected as part of ageing. An objective cognitive impairment that
is not severe enough to have a significant impact on daily activities
is oGen referred to as a mild cognitive impairment. This is a risk
factor for future dementia (Petersen 2001).
Dementia and cognitive decline are major public health issues.
There are currently more than 40 million people worldwide with
dementia due to AD, the most common subtype, and this number
is projected to increase to more than 100 million by 2050 (Prince
2016). Dementia costs were estimated at USD 818,000 million in
2015, equivalent to 1.1% of global gross domestic product. It is
estimated that by 2030, the global cost of dementia could grow to
USD 2,000,000 million, which could overwhelm health and social
care systems (Wimo 2017). The total cost of dementia to the UK
alone is GBP 34,700, million, of which GBP 4,900 million is paid by
the National Health Service (NHS) and GBP 15,700 million is paid
by social care. The remainder is paid by those living with dementia
and their families, and is classified as unpaid social care or private
care (Alzheimer's Society 2019).
A number of prognostic factors have been associated with the onset
of dementia, including age, sex, premorbid intelligence, genetics,
medical conditions (e.g. diabetes, hypertension), and lifestyle
factors (e.g. physical inactivity) (Livingston 2017). Identification
of prognostic factors could assist healthcare professionals in
predicting outcomes for individuals with cognitive syndromes and
help policymakers in planning for future population healthcare
needs. Identification of modifiable prognostic factors oFers
potential targets for preventing or delaying the onset of cognitive
decline and dementia.
Description of the prognostic factor
A prognostic factor is any measure that is associated with a future
clinical outcome. The prognostic factor of interest for this review is
anticholinergic burden.
A wide range of medications commonly used in older adults have
anticholinergic properties. Some medications, such as oxybutynin
(for overactive bladder), exert their intended eFects through
their anticholinergic activity. For other medications, such as
amitriptyline for depression, anticholinergic activity is probably
incidental to their intended mechanism of action. It is common for
older adults to be taking multiple medications with anticholinergic
eFects (Myint 2015).
Even medications that have low anticholinergic activity
individually may contribute to a significant overall anticholinergic
eFect if a person is taking several of them. This can be quantified as
the anticholinergic burden (ACB). There is a reported relationship
between ACB and various adverse health outcomes (Singh 2008). It
has been suggested that exposure to high ACB is associated with
cognitive decline and dementia in older adults (Fox 2014).
ACB measures are used in primary and secondary care as part
of the medication review process. Such reviews are increasingly
recommended for older adults. The quantification of ACB is
designed to assess risk of future adverse events. Based on the
ACB score, clinicians may recommend reducing or replacing
certain medications. Use of measures of ACB to guide treatment
decisions is entering clinical practice. The most recent National
Institute for Health and Care Excellence (NICE) dementia guideline
recommends considering ACB as a factor that may be contributing
to cognitive impairment and suggests using a validated scale to
measure ACB (NICE 2018). To date, ACB has been considered largely
as a ‘stand-alone’ prognostic factor (not as part of a multifactorial
prediction model).
Measures of ACB
ACB can be measured using a variety of approaches. There
is no consensus on which ACB measures provide the most
accurate and clinically useful prognostic information. Generally,
ACB measures use a person's medication list and assign a score
to certain medications. A cumulative total based on all prescribed
medications is then calculated. Although these measures should be
similar, they have been developed using diFerent methods and so
include diFering medications and assign diFering scores to these
medications.
Our literature scoping suggests that 10 tools to measure ACB have
been published. In a large population cohort (UK Biobank) (Hanlon
2019), it was reported that ACB was strongly associated with future
adverse health outcomes regardless of which ACB measure is used.
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However, at the individual patient level there was substantial
variability in the ACB score generated by each measure. The overlap
between measures is limited, and so any prognostic review should
be completed at the individual scale level in addition to trying to
create summary estimates for all ACB measures.
Prior to adoption in clinical practice, there should be a
comprehensive assessment of the available literature to describe
whether ACB is a true prognostic factor, particularly aGer adjusting
for other dementia risk factors that may also be associated with
anticholinergic prescribing. If ACB is a prognostic factor, the
strength of the association and the quality of the supporting
evidence should also be described. Looking at the prognostic
properties of each ACB measure may assist in choosing a preferred
scale.
Why is it important to do this review?
This increasing clinical interest in ACB is accompanied by a growth
in the research literature on ACB as a prognostic factor. However,
results from individual studies of ACB and cognition or dementia
are conflicting, and not all published papers have followed best
practice in design, conduct, or reporting. There is thus uncertainty
around the clinical utility of ACB and consequently inconsistency in
clinical practice and guideline recommendations. In this systematic
review, we aim to estimate the prognostic utility (adjusted and
unadjusted) of diFerent ACB measures for predicting dementia or
cognitive decline in a cognitively healthy older adult population
and to assess the quality of the supporting evidence. The review
has the potential for an immediate impact on practice, particularly
if ACB measures have demonstrably diFerent prognostic utility.
Our scoping suggests that certain measures will have suFicient
published data to allow for a meta-analytical approach to
describing summary prognostic utility. For other measures, our
scoping suggests there may be no relevant papers. This lack of
evidence would still represent an important finding, particularly in
the context of increasing enthusiasm for the clinical application of
these measures.
It will take a randomised controlled trial to definitively show
whether using ACB measures can guide deprescribing of
anticholinergic medications in older adults and whether such an
intervention is clinically eFective, cost-eFective, and safe. Our
review may inform such a trial by suggesting the preferred method
for quantifying ACB. Whilst we await this definitive evidence of the
utility of the ACB concept, our proposed review will oFer a critical
summary of the evidence around ACB as a prognostic factor.
O B J E C T I V E S
Primary objective: to assess whether ACB in older adults is a
prognostic factor for future cognitive decline or dementia.
Secondary objective(s): to assess whether ACB is a prognostic
factor for older adults recruited in primary care, secondary care,
or community settings (with setting used as the basis for subgroup
analyses); whether ACB is associated with mortality; to compare
the prognostic validity of respective ACB scales; and to examine the
eFect of duration of exposure and duration of follow-up on the ACB-
dementia risk association.
M E T H O D S
We will follow best practice in design, conduct, and reporting of
our prognosis review as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions (Cochrane 2019). The review
will be supported by the Cochrane Prognostic Methods Group,
partners within the Cochrane Mental Health and Neuroscience
Network, and the UK National Institute for Health Research
Complex Reviews Support Unit (NIHR CRSU).
We used the PICOT (Patient/Problem; Intervention; Comparison;
Outcome; Timing) system to design our review question (Schardt
2007). As recommended by the Cochrane Prognosis Methods
Group, we will follow MOOSE (meta-analysis of observational
studies in epidemiology) guidelines, complemented by REMARK
(Reporting Recommendations for Tumor Marker Prognostic
Studies), to ensure that our review is designed, conducted, and




Population Older adults (mean age of 50 years and above) free of cognitive impairment at baseline
Interventions Anticholinergic burden as measured by any validated ordinal anticholinergic burden scale
Comparators (covariates of in-
terest)
Age, sex, and comorbidity
Outcomes Incident dementia or cognitive function (multidomain)
Type of study Longitudinal, observational cohort/case-control
Timing and setting Recruitment from primary, secondary, or community settings
Minimum of 1-year follow-up
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Selection criteria
Types of studies
We will include prospective and retrospective longitudinal cohort
and case-control observational studies. We will not include cross-
sectional studies, as it is not possible to determine prognosis from
this design. We will not include prospective case studies, defined
here as having fewer than 20 participants. We will exclude studies
that are published only as abstracts or posters at conferences, as
these have not undergone peer review.
Types of participants
We will include any studies that recruited older adults (as defined
by the authors, but with minimum median/mean age 50 years at
baseline) who were free of any known cognitive diagnosis (mild
cognitive impairment, dementia, delirium) at time of recruitment
and at time of application of the ACB measure. We will not exclude
studies that did not assess cognition at baseline; however, where
a mixed population was recruited, we will only include the study
in the review if the prevalence of dementia is less than 7% in a
community sample (similar to general population prevalence in
unselected older adults). We will also include studies that recruited
mixed populations in a hospital setting, where the prevalence
of dementia may be higher, provided that it is conducted in an
unselected sample. A separate prognosis review is planned to look
at the prognostic utility of ACB in people living with cognitive
syndromes. This future review will complement the findings of the
present review by expanding our findings to ACB risk for cognitive
decline in those who already demonstrate cognitive issues. We will
make no other restriction based on comorbidity or polypharmacy,
but will record these factors in our data extraction. We will assess
whether comorbid conditions that are associated with dementia
(depression, stroke, other neurological diseases) were measured
and consider any potential impact of this in our 'Risk of bias'
assessment. We will include studies conducted in specific patient
subgroups, such as Parkinson’s disease or stroke, provided they
meet our other inclusion criteria. We believe these criteria will give a
population representative of the people in whom ACB may be used
in clinical practice.
Index prognostic factor
The prognostic factor of interest is anticholinergic burden. We
will include any study that used an ordinal scale that purports to
measure cumulative exposure to medications with anticholinergic
properties. Scales need not be described as validated for prediction
of cognitive outcomes. Previously identified scales are listed in
Appendix 1.
DiFerent approaches to quantifying ACB have been used. Some
scales sum ordinal scores for each relevant drug to give a
continuous measure; others create a summary ordinal hierarchical
measure that scores, for example, 0 to 3 or 0 to 4 based on the
cumulative anticholinergic exposure. Most scales define thresholds
of ‘low’ and ‘high’ burden. As our focus in this review is on the extent
of anticholinergic burden, we will not include studies that assess
anticholinergic exposure via a simple dichotomised present/absent
scale.
Some ACB measures were developed specifically to predict
dementia, whilst others were developed to predict other adverse
events, including death. Anticholinergic activity should be an
objective drug eFect, and so we will include any ACB measure, not
just those developed for cognitive outcomes.
We have not chosen a particular measure of primary interest as
there is no consensus on the preferred measure, and there is
substantial heterogeneity in clinical practice. However, if the Drug
Burden Index (DBI) scale is utilised, we will only include data if ACB
data are reported separately.
Comparator prognostic factors
We are interested in the value of ACB as a prognostic factor
over and above other prognostic factors that may be common in
this population. Hence, whilst we will include studies that only
assessed the unadjusted ACB prognosis, we will also evaluate
the prognostic eFect of ACB aGer adjustment for core variables
identified as fundamental to the putative link between ACB and
dementia. These variables were selected on the basis of a Delphi
discussion between the review authors and a wider multicentre
collaborative working in the field of ACB research. The chosen
core variables are: age, sex, and comorbidity. We recognise that
comorbidity may be described in various ways. We will accept
any classification that the original study authors define as a
measure of comorbidity, including measures that oFer quantitative
data, for example number of medications, number of medical
conditions listed, or formal measures such as the Charlson Index.
We will assess use of additional adjustments in our 'Risk of bias'
assessment.
Outcome measures
Primary outcome: We will include any study that assesses incident
dementia or cognitive decline (i.e. change on a measure of cognitive
function) as an outcome. We will accept any validated diagnostic
criteria for dementia.
For the outcome of cognitive decline, we will accept any
multidomain cognitive assessment tool that is validated for the
direct assessment of cognition. We will not include papers that only
measure a single cognitive domain.
Secondary outcome: We will include overall survival and
dementia-free survival as secondary outcomes in studies that
measure cognitive outcomes or incidence of dementia.
Timing: We will accept assessment for dementia or cognitive
decline at any time greater than or equal to one year following
baseline ACB assessment so as to mitigate the risk of reverse
causality between any observed risk associations. We anticipate
that most studies will have a follow-up of at least one year to allow
time for outcomes to develop. If possible, we will collate outcomes
at common time periods, for example one year, two years, three
years.
Setting: We will include studies where initial recruitment was in
primary care, secondary care, and community settings. We will
define primary care as settings in which the patient self-presents
to a non-specialist service, such as general practice. We will
define secondary care as any settings where patients are referred
for expert care, including general hospitals and more specialist
settings. We will define community settings as settings in which
the cohort is completely unselected, that is ‘population screening’.
Prevalence of dementia is likely to be lower in such settings than in
secondary or primary care. As this review is focused on prognosis
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in people who are cognitively well, we will not include studies
conducted in care-home settings where the prevalence of cognitive
syndromes is substantial.
Search methods for identification of studies
Electronic searches
As reporting of prognostic factor studies is variable, it can be
challenging to identify all relevant studies. We will adopt the
procedure proposed by Geersing 2012 to maximise our ability
to identify relevant prognostic studies. Specifically, as we are
searching for one prognostic factor, we will not adopt any specific
search filter, but will instead adopt a search that combines our
prognostic factor (ACB) with the disease outcome (dementia/
cognitive impairment). Search strategy can be seen in Appendix 2.
We will search the following databases from inception year to
present date: the Cochrane Dementia and Cognitive Improvement
Group Specialised Register, Ovid Medline, Ovid Embase, APA
(American Psychological Association) PsycInfo, EBSCO’s (Elton B.
Stephens Co.) CINAHL (Cumulative Index to Nursing and Allied
Health Literature), and ISI Web of Science Core Collection.
Searching other resources
We will supplement this with handsearches of all included studies
and identified systematic reviews and will contact study authors for
missing data where required.
Data collection and analysis
Selection of studies
We will use Covidence systematic review soGware (Covidence) to
identify relevant studies. Two review authors will independently
screen studies identified via our search method. Titles and
abstracts will be screened in the first instance, with the full text
of potentially relevant studies then accessed to determine if the
study meets our inclusion criteria. In case of disagreement, a third
review author will act as arbiter and make the final decision on
study inclusion/exclusion. We will illustrate the results of the search
using a PRISMA flow chart (Moher 2009).
Data extraction and management
Two review authors will extract the data to a piloted pro forma
based on the CHARMS-PF (CHecklist for critical Appraisal and data
extraction for systematic Reviews of prediction Modelling Studies,
adapted for prognostic factors) template (Riley 2019). We will
contact authors for missing data where required. We will select two
studies, Richardson 2018; Gray 2015, with which to trial our data
extraction pro forma. We will extract all data onto a standard form
containing the following information.
Contents of data extraction pro forma
 
Extracted information Included details
General information Author, title, source, publication date, language, related or duplicate publications
Source of data Cohort (retrospective or prospective data collection), case-control, randomised trial, or secondary
analysis of registry data
Participant information Participant eligibility and recruitment method (e.g. consecutive or other recruitment, number of
centres, inclusion and exclusion criteria); participant demographics (e.g. age, sex); details of ongo-
ing treatments/medications; study dates; country of recruitment; setting (using our definitions of
primary, secondary, and community settings)
Prognostic factor Definition and method of measurement of prognostic factor. We do not expect duration of expo-
sure (pre- or post-study commencement) to be regularly recorded; however, where possible, we
will record timing of prognostic factor measurement (number of weeks participants have been on
the ACB drugs prior to baseline assessment); where data are available we will also collect duration
of exposure during the study.
Outcomes to be predicted Definition and method of measurement of outcome; time of outcome ascertainment, or summary
of duration of follow-up, overall survival, and dementia-free survival
Adjustment for other prognos-
tic factors (covariates)
List of all the covariates that were adjusted for in any regression model
Sample size Number of participants and number of outcomes/events; how missing data were handled (e.g.
complete-case analysis, imputation, or other methods)
Reported results We will record incidence of dementia and cognitive decline. Data on incident dementia are likely to
be in the form of hazard ratios. Where possible, we will extract estimates and corresponding confi-
dence intervals from each included paper. Change in validated cognitive assessment data may be
presented as continuous data or as events with hazard ratios (e.g. time till cognitive score declines
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
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below a particular value). We will also record overall survival (including duration of follow-up) and
dementia-free survival (including duration of follow-up).
 
Assessment of methodological quality
Two review authors will independently use the QUIPS (Quality
in Prognosis Studies) checklist (Hayden 2012), assessing the
included studies across the domains of: study participation; study
attrition; prognostic factor measurement; outcome measurement;
adjustment for covariates; statistical analyses and reporting. We
will take the QUIPS anchoring statements but modify content to
suit our review topic based on consensus within the review author
team. We will judge each domain as low risk of bias, moderate risk
of bias, or high risk of bias.
Specific considerations for this review: We will assess issues with
risk of bias around the following.
• Study participation: We will consider whether the method
of recruitment is at risk of selection bias (e.g. consecutive
recruitment versus convenience sample) and if there is
adequate reporting of comorbidities and demographics (age
and sex). If either a convenience sample was used or there was
inadequate reporting of comorbidities/demographics, we will
assign a moderate risk of bias.
• Attrition: We anticipate that most studies will utilise databases,
hence attrition will be less of an issue. We will therefore focus
on reporting of, and methods for dealing with, missing data. We
will assign a moderate risk of bias if no analysis was carried out
to evaluate if participants with missing data diFered in baseline
ACB score compared to those with full data.
• Prognostic factor measurement: We will consider how
medication data was obtained. If medication was not
established via at least two methods and capable of establishing
non-prescription medications taken, along with duration of
exposure and adherence, we will assign a moderate risk of bias.
If repeated ACB measurements were not made over time for
studies with a greater than one-year follow-up duration, we will
assign a high risk of bias. We anticipate that some studies may
utilise validated ACB scales but tweak these scales, for instance
to incorporate dosage into the anticholinergic calculation. We
will not consider utilisation of ACB scales as part of the 'Risk of
bias' assessment, as it is the purpose of the review to establish
which ACB scales have the greatest prognostic accuracy.
• Outcome measurement: We will consider the method utilised
for dealing with missing data in relation to the outcome. If
‘last diagnosis carried forward’ was used when final outcome
data were not available, we will assign a high risk of bias. We
will assess whether the outcome was established via a clinical
follow-up or was reliant upon database diagnoses. If outcome
was reliant upon database diagnoses alone, we will assign a
moderate risk of bias. We will also assess if the outcome was
determined without knowledge of the prognostic factor, and
assign a high risk of bias if there was no blinding to outcome.
• Covariates: We will assess whether studies adjusted for age,
sex, and comorbidities as a minimum. If these covariates were
not adjusted for, we will assign a high risk of bias. Assessment
for comorbidities should control for at least three comorbidities
that cover both physical and psychiatric domains; failure to do
so will result in a rating of moderate risk of bias.
• Reverse causation: We will evaluate studies regarding
perceived risk that anticholinergic drug use was prescribed for
treatment of early signs of dementia. If a study does not restrict
ACB measurement to 12 months before dementia onset, we will
assign a high risk of bias.
• Statistical analysis: We will evaluate how the analysis
was conducted. We will assign a high risk of bias if: a
multivariate analysis was not conducted; if the analysis was not
appropriately powered based on the ‘10 events per covariate’;
if the method for selecting covariates for inclusion in a
multivariate model was based on P values in a univariate
analysis without incorporation of prior knowledge of relevant
associations into selection; if the method of analysis was
consistent with the stated protocol; and if the reported results
are consistent with the stated method of analysis. We will
assign a moderate risk of bias if relevant assumptions were not
checked.
Specific issues of consideration in each area were decided upon via
discussion amongst the review authors.
Discussing reporting deficiencies: Prognosis research is oGen
confounded by poor reporting and possible publication bias.
We will supplement our 'Risk of bias' assessment with a
narrative discussion of reporting issues, highlighting when missing
information may aFect results. Prognostic factor studies oGen
do not register protocols, increasing the risk that not all studies
(published and unpublished) will be identified, and there is a risk
of small-study eFects (in which smaller studies with higher odds
ratios are more likely to be published than smaller studies with
non-significant odds ratios), which can bias meta-analyses (Peat
2014; Riley 2019). We will use sensitive search filters for the disease
(dementia) and the prognostic factor (ACB burden) without any
specific filter for prognostic research to increase retrieval, and will
also examine the likelihood of small-study eFects in our review by
generating a funnel plot.
Data synthesis
To investigate the ACB association with our primary and secondary
outcomes, we will evaluate ACB scores as an ordinal, hierarchical
variable. We will oFer summary estimates for each ACB tool, and
as an exploratory analysis (if data allow) we will also describe
a summary estimate including all ACB measures. We will pool
data in three separate ways. In the first instance, we will pool
data obtained from unadjusted analyses. In the second instance,
we will pool data from fully adjusted analyses, provided age,
sex, and comorbidity were controlled for as a minimum. And
as a final exploratory analysis, we will pool data from the most
adjusted model (i.e. the model adjusting for the greatest number
of variables) presented. We will pool odds, hazard, risk ratios
and correlations separately. Where data are not available, we will
attempt to estimate data based on methods suggested by Tierney
2007. Where data are suFiciently similar to permit pooling, we
will use a random-eFects approach given our expectation of high
heterogeneity between studies. We will use Comprehensive Meta-
Analysis soGware (Borenstein 2013) to conduct all meta-analyses.
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
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If time and data allow, we will attempt comparative analyses of the
diFering ACB measures. We will work with the team from the NIHR
CRSU on this aspect of the analysis.
We will assess exposure including exposure before enrolment into
the study and exposure during the course of the study. Where data
allow, we will create categories of < 1 year, 1 to 5 years, and >
5 years. In a sensitivity analysis, we will remove studies with < 1
year exposure. If there are suFicient papers, we will run a subgroup
analysis looking at 1 to 5 years and > 5 years individually.
We will assess duration of follow-up. Where data allow, we will
create categories of < 1 year, 1 to 5 years, and > 5 years. In a
sensitivity analysis, we will remove studies with < 1 year follow-
up. If there are suFicient papers, we will run a subgroup analysis
looking at 1 to 5 years and > 5 years individually.
We will also conduct a subgroup analysis via setting. These
additional outcomes were decided upon through discussion
amongst the review authors.
Finally, we will conduct a sensitivity analysis restricted to studies
that scored as low risk of bias in all respective domains.
Investigation/description of heterogeneity
We will investigate and describe statistical heterogeneity via the I2
statistic (I2 greater than 30% represents moderate heterogeneity;
I2 greater than 75% considerable heterogeneity) (Higgins 2003).
Where data allow, we will conduct a meta-regression based on
study recruitment setting (primary versus secondary care versus
community care), comorbidity, and polypharmacy in our analysis
of heterogeneity.
Grading the evidence
We will use the GRADE approach to evaluate our overall confidence
in the results. We will adapt the GRADE approach to suit prognosis
research in a fashion consistent with Huguet 2013. Specifically, we
will evaluate reported evidence in the following eight areas.
1. Phase of investigation: Phase 3 explanatory studies derived
from bespoke cohort study designs that seek to explain the
mechanisms behind an underlying association between ACB
and dementia/cognition will be considered a high level of
evidence. Phase 2 explanatory studies that seek to confirm an
independent association between ACB and dementia/cognition
will be treated as moderate evidence, and hypothesis generating
phase 1 explanatory studies will be treated as weak evidence for
any association between ACB and dementia/cognition.
2. Study limitations: We will use the previously described QUIPS
tool to evaluate the overall risk of bias of included studies. Our
GRADE judgement will be based upon the overall quality of the
evidence, i.e. if most (> 50%) included studies are considered
to be at high risk of bias in their reported association between
ACB and dementia/cognition, we will downgrade the evidence
accordingly.
3. Inconsistency: We will downgrade the evidence if associations
between ACB and dementia/cognition are heterogeneous (i.e.
the reported odds/hazard ratios fall either side of 1.0 on a forest
plot); if the I2 statistic is substantial (i.e. 75%); and if the P value
is low for the test of the null hypothesis that all studies in a meta-
analysis have the same underlying magnitude eFect.
4. Indirectness: We will downgrade the studies where their
investigation does not fully match with our broader review
question. We will consider two areas of indirectness when
judging if evidence should be downgraded on this basis:
a. if the population in the included studies only represents a
subset of the population of interest (e.g. if only very old, i.e.
> 80 years, were assessed);
b. if the outcome investigated in the included studies is overly
restricted, e.g. if the included studies explored only the
association between ACB and Alzheimer's dementia, then
the evidence for the association between ACB and all-cause
dementia would be downgraded for indirectness.
5. Imprecision: We will downgrade the evidence if there are
insuFicient numbers in the meta-analysis or if the confidence
intervals are wide. We will not set an absolute value, but will
assess this in the context of eFect size and minimally important
clinical diFerence. If a meta-analysis is not possible, we will
evaluate imprecision on the basis of study power and reported
confidence intervals within individual studies. We will also
downgrade the evidence if estimation of hazard/odds ratios
using summary data employing methods described by Tierney
2007 is required.
6. Publication bias: Due to inherent issues regarding publication
bias in prognostic research, we will adopt the default position
that publication bias is likely and downgrade the evidence
unless our assessment of publication bias provides significant
evidence to the contrary (i.e. a symmetrically distributed
funnel plot, and evidence that the prognostic factor has been
investigated in a large number of cohort studies).
7. E@ect size: We will upgrade our confidence in the eFect estimate
if the eFect size is moderate to large (e.g. a hazard ratio of 2.5 or
above).
8. Exposure-response gradient: We will upgrade our confidence
in the eFect estimate if there is evidence (via subgroup analysis)
that a longer duration of ACB is associated with an increased
risk of dementia/cognitive decline. Similarly, we will upgrade
the evidence if there is an incremental increase in eFect size with
increasing ACB.
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A P P E N D I C E S
Appendix 1. Anticholinergic burden scales
AAS: Anticholinergic activity scale
AAS-r: Revised anticholinergic activity scale
ACB: Anticholinergic burden
ACoB: Anticholinergic cognitive burden
ADS: Anticholinergic drug scale
AEC: Anticholinergic eFect on cognition
AIS: Anticholinergic impregnation scale
ALS: Anticholinergic loading scale
ARS: Anticholinergic risk scale
CrAS: Clinician-rated anticholinergic scale
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13. ("chew* score" or "chew* list").ti,ab.



















33. Mild Cognitive Impairment/







41. major neurocognitive disorder*.ti,ab.
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